vx 509 Search Results


decernotinib  (MedChemExpress)
93
MedChemExpress decernotinib
JAK2 inhibitors inhibit proliferation, while JAK1/3 inhibitors do not. A-D: SeAx cells were seeded at a cell density of 50,000 cells per well in a 96 wells plate. After incubation for 48 h with AZD1480, <t>decernotinib,</t> ruxolitinib and tofacitinib, viability was quantitated. E: IC 50 values were determined for AZD1480 and ruxolitinib. Error bars represent SD of three separate experiments. ****P < 0.0001 versus AZD1480.
Decernotinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx+509/Decernotinib/pmc07569298-51-7-8
Average 93 stars, based on 1 article reviews
decernotinib - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
vx-509 (decernotinib)  (Hoock GmbH)
90
Hoock GmbH vx-509 (decernotinib)
JAK2 inhibitors inhibit proliferation, while JAK1/3 inhibitors do not. A-D: SeAx cells were seeded at a cell density of 50,000 cells per well in a 96 wells plate. After incubation for 48 h with AZD1480, <t>decernotinib,</t> ruxolitinib and tofacitinib, viability was quantitated. E: IC 50 values were determined for AZD1480 and ruxolitinib. Error bars represent SD of three separate experiments. ****P < 0.0001 versus AZD1480.
Vx 509 (Decernotinib), supplied by Hoock GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx+509/vx+509++decernotinib+/pm28555727-600-25-7
Average 90 stars, based on 1 article reviews
vx-509 (decernotinib) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
vx 509  (Vertex Pharmaceuticals)
86
Vertex Pharmaceuticals vx 509
JAK2 inhibitors inhibit proliferation, while JAK1/3 inhibitors do not. A-D: SeAx cells were seeded at a cell density of 50,000 cells per well in a 96 wells plate. After incubation for 48 h with AZD1480, <t>decernotinib,</t> ruxolitinib and tofacitinib, viability was quantitated. E: IC 50 values were determined for AZD1480 and ruxolitinib. Error bars represent SD of three separate experiments. ****P < 0.0001 versus AZD1480.
Vx 509, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vx+509/509+vx/pm34949146-73-4-13
Average 86 stars, based on 1 article reviews
vx 509 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
vx 509  (Cayman Chemical)
N/A
VX 509 is a selective inhibitor of Janus kinase 3 JAK3 with a K value of 2 5 nM in enzyme assays and an IC value of 50 170 nM in cellular assays dependent on
   Buy from Supplier
decernotinib (vx-509)  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier

Image Search Results


JAK2 inhibitors inhibit proliferation, while JAK1/3 inhibitors do not. A-D: SeAx cells were seeded at a cell density of 50,000 cells per well in a 96 wells plate. After incubation for 48 h with AZD1480, decernotinib, ruxolitinib and tofacitinib, viability was quantitated. E: IC 50 values were determined for AZD1480 and ruxolitinib. Error bars represent SD of three separate experiments. ****P < 0.0001 versus AZD1480.

Journal: Biochemistry and Biophysics Reports

Article Title: Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells

doi: 10.1016/j.bbrep.2020.100832

Figure Lengend Snippet: JAK2 inhibitors inhibit proliferation, while JAK1/3 inhibitors do not. A-D: SeAx cells were seeded at a cell density of 50,000 cells per well in a 96 wells plate. After incubation for 48 h with AZD1480, decernotinib, ruxolitinib and tofacitinib, viability was quantitated. E: IC 50 values were determined for AZD1480 and ruxolitinib. Error bars represent SD of three separate experiments. ****P < 0.0001 versus AZD1480.

Article Snippet: JAK inhibitors (JAKi) AZD1480 (Tocris, Bristol, UK), decernotinib (MedChem Express, Monmouth Junction, NJ), ruxolitinib (Selleck, Houston, TX) and tofacitinib (Pfizer, Capelle a/d Ijssel, The Netherlands) were dissolved in DMSO to a concentration of 10 mM.

Techniques: Incubation